236 results about "Cell subpopulations" patented technology

Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The present invention relates to methods and products for assessing autophagic flux, and more specifically provides a biochemical functional measure used to quantify autophagic flux in sub-populations of blood cells. The present invention also provides lysosomal system markers for use in the methods described herein, systems for assessing autophagic flux, methods of identifying markers indicative of autophagic flux, and methods of treating subjects found to be suffering from, or susceptible to, a disease, condition or state associated with autophagic flux dysfunction using the methods described herein.

The invention provides a method and system for analyzing lung cancer brain metastasis organoid cell subpopulation and functional characteristics, and the method comprises a series of steps: data quality control, batch effect removal, cell grouping, copy number variation inference, quasi-time sequence analysis, function enrichment analysis, and drug sensitivity analysis before and after radiotherapy. Single cell transcriptome sequencing data obtained after organoid culture is subjected to personalized analysis, heterogeneity of tumor cells and sensitivity of the tumor cells to drugs after radiotherapy are described, and the characteristics of all cell subgroups in the lung cancer brain metastasis organoid and the effect of the cell subgroups in the tumor microenvironment can be accurately analyzed; powerful support is provided for mechanism research and precise medicine of lung cancer brain metastasis.

The invention provides a new bunyavirus neutralizing antibody screening method based on single cell BCR sequencing. The new bunyavirus neutralizing antibody screening method comprises the following steps: S1, collecting peripheral blood B cells of acute stage and recovery stage patients and healthy volunteers of new bunyavirus infected persons; s2, carrying out CD19 < + > CD38 < + > CD138 < + > magnetic bead separation to obtain a single-cell suspension; s3, constructing a single cell transcriptome and a BCR library, separating single cells by using a microfluidic system, and performing high-throughput sequencing; s4, analyzing a B cell subset, a BCR cloning amplification mode and a VJ gene pair enrichment characteristic through bioinformatics analysis; and S5, screening a specific BCR clone type related to the severity of the disease as a neutralizing antibody candidate target. The method provided by the invention provides powerful support for immune monitoring and vaccine design of new bunyavirus infection, and is expected to provide new strategies and methods for clinical treatment and prevention.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.

The invention belongs to the technical field of cell biology, and particularly relates to a preparation method of tumor enhanced targeting and therapeutic function extracellular vesicles and a chip device. The invention firstly provides an integrated chip device which is provided with a cell screening module and a functional preparation module and comprises a plurality of functional layers, wherein one functional layer is provided with a cell evolution screening area with gradient for cell screening, and the other functional layer is provided with a cell electric remodeling area for cell functionalization transformation. The invention innovatively proposes that tumor cells with strong metastasis ability are screened based on culture gradient, the tumor cells with stronger invasion ability are distinguished by utilizing spatial segmentation, then the screened cell subpopulation is transferred to a cell electric remodeling area in combination with overturning operation of the chip, and the cell subpopulation is transferred to the cell electric remodeling area in a manner of focusing an electric field through nanopores. And meanwhile, therapeutic molecules are efficiently delivered to realize cell transformation, so that the transformed cells can enhance the output of extracellular vesicles with a therapeutic function.

The invention discloses a screening method of sicca syndrome markers based on conjunctival blotting, and relates to the technical field of biomedicine, and the screening method comprises the following steps: S1, conjunctival noninvasive sampling; s2, RNA (Ribonucleic Acid) sequencing and pathway screening; s3, machine learning modeling is carried out; s4, clinical verification. According to the invention, biomarker screening is realized, and similar biomarker screening can also be realized through tear sample analysis or other ophthalmic samples; however, the alternative schemes have the defects of relatively strong invasiveness, complex operation and the like; sampling is carried out through the conjunctival imprinting technology, invasive operation such as biopsy and blood drawing is avoided, and pain and discomfort are reduced; differential expression genes can be accurately identified, and the sensitivity and the accuracy are relatively high; through immune cell infiltration analysis, the relationship between the immune cell subpopulation and the sicca syndrome related gene is disclosed, a new perspective is provided for a disease mechanism, and a theoretical basis is provided for a future immune regulation strategy.

The invention provides a single-cell multi-omics data clustering method based on a diffusion auto-encoder, and belongs to the technical field of biological single-cell data classification. Comprising the following steps: carrying out dimension reduction processing on paired single-cell omics A and omics B data to obtain two types of omics data with consistent dimensions; integrating the features of the two types of omics data by using a feature fusion module based on a bidirectional cross attention mechanism to obtain common semantic embedding z of the cells; generating random encoder features based on the two types of omics data, and reconstructing original data based on z and the random encoder features by using two conditional diffusion models; updating parameters of the conditional diffusion model by using a loss function to obtain a common semantic embedding z'which minimizes the loss function; and dividing the cells into different cell subgroups by using z'by using a clustering algorithm. According to the method, the semantic features and random noise of the cells are separated by using decoupling learning, and the cells are clustered by using cross-omics invariant features, so that different subtypes can be accurately identified.

The invention provides a dynamic regulation and control method for optimizing CAR-T cell amplification conditions, which comprises the following steps: acquiring high-frequency cell activity monitoring data from a cell culture system, and extracting metabolic marker fluctuation and proliferation rate mutation from the high-frequency cell activity monitoring data to obtain real-time cell state parameters; comparing the real-time cell state parameters with a T cell subset proportion and a cell factor release mode in historical immune data of the patient to obtain a cell state deviation value, and determining an abnormal fluctuation condition of proliferation rate mutation according to the cell state deviation value; if the abnormal fluctuation of the proliferation rate mutation exceeds a preset fluctuation threshold value, capturing proliferation signal abnormity by analyzing metabolic marker fluctuation and metabolic waste accumulation according to the cell state deviation value; according to the targeted culture parameter set, adjusting the oxygen supply quantity and the culture solution microenvironment of an oxygen concentration control system to obtain a culture environment for inhibiting cytokine storm and proliferation signal abnormity.

The invention discloses a progressive multiple sclerosis differential diagnosis marker based on immunophenomics and application of the progressive multiple sclerosis differential diagnosis marker. The invention specifically provides an immune biomarker set for identifying progressive or recurrent remission type multiple sclerosis and a corresponding reagent and kit thereof. The immune biological marker provided by the invention comprises one or more of the following groups: a) activating a T cell subset; b) a CD28 < + > and CD28-T cell subset; c) forming a subgroup by the CD8 + T cells; and d) a MAIT cell subset category. The immune biomarker disclosed by the invention can also be applied in a multi-index combination manner, and can be applied to a) multiple sclerosis patients which are not subjected to disease modification treatment; b) a patient with multiple sclerosis treated by disease modification; and c) a very good effect of distinguishing clinical subtypes of the multiple sclerosis can be achieved in the three types of people of the multiple sclerosis patients who do not distinguish whether the multiple sclerosis patients are subjected to the disease modification treatment or not.

The invention discloses application of T cell subgroups in preparation of a kit for evaluating B cell depletion therapy and application of the T cell subgroups in preparation of the kit for evaluating B cell depletion therapy, the T cell subgroups comprise one or more of CD4 + TCM, CD4 + TEM, CD8 + TCM, CD8 + TEM, CD20 dimCD4 + TCM, CD20 dimCD4 + TCM, CD20 dimCD8 + TEM, Th17.1, Th17, Th2, CD4 + TCMTh17.1, CD4 + TEMTh17 and CD4 + TEMTh2, and the T cell subgroups comprise one or more of CD4 + TCMTh17, CD4 + TEMTh17 and CD4 + TEMTh2.

To provide a cell proliferation system, proliferation method, control method, and culture medium bag capable of proliferating various adherent cells and suspension cells. [Solution] Cells are grown in a bioreactor and activated by an activator (e.g., a soluble activator complex). The nutrient supply and gas exchange functions of an automated closed cell proliferation system make it possible to seed at, for example, a low seeding density. By manipulating the parameters of the cell growth environment, cells are placed in specific locations within the bioreactor for efficient exchange of nutrients and gases. System parameters are adjusted to shear any cell colonies that may form during the proliferation phase. Metabolic concentrations are controlled to improve cell growth and viability. Cell retention within the bioreactor is controlled. In some embodiments, the cells include T cells. In other embodiments, the cells include a T cell subpopulation, for example, regulatory T cells (Tregs).

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

The invention provides a lung adenocarcinoma immune cell subset network marker screening method. According to the lung adenocarcinoma immune cell subset network marker screening method, a lung adenocarcinoma immune cell subset network marker screening model with specificity and accuracy is constructed, and a network marker capable of accurately representing immune cell subset characteristics is screened out; meanwhile, by establishing a high-interpretability cell classification model based on the network markers and adopting the relevance between the network markers and cell classification results, the cell classification performance is improved, and effective and reliable verification of the network markers is achieved. Finally, a lung adenocarcinoma immune cell subset spatial relationship analysis algorithm based on the network marker regulatory relationship is constructed, the limitation of a high-cost spatial imaging technology is broken through, the correlation between the regulatory relationship between the network markers and immune cell spatial distribution is disclosed, and clues are provided for understanding a cell interaction mechanism in a tumor microenvironment.

Methods are disclosed for adding adapters to fragmented nucleic acids for next generation sequencing, including providing numerical codes based on variable adapter molecular barcode lengths on both sides of the fragmented nucleic acids and identifying reads from the same fragment based on both barcodes. The methods and products allow for the amplification of the fragmented nucleic acids when there is a low yield of isolated fragmented nucleic acids and also for efficient and reliable detection of low-frequency mutations including in subpopulations of cells within a subject.

The invention discloses a preparation method of a silicon dioxide nano vaccine for mediating constant natural killer T (iNKT) cells and application of the silicon dioxide nano vaccine in the field of tumor immunotherapy. The iNKT cell is a special T cell subset which can be activated by a glycolipid antigen presented by CD1d, and can directly kill tumor cells and activate other immune cells. Clinically, the classical agonist alpha GC of the iNKT cell can lead to function depletion of the iNKT cell after multiple intravenous administration, and finally evolves into an inactive state. Although the CD1d / alpha GC protein complex relieves the iNKT cell anenergetic state to a certain extent, the CD1d / alpha GC protein complex is easily degraded and cleared in a complex physiological environment, and the treatment effect is weakened. The characteristics of large aperture and high specific surface area of dendritic mesoporous silica are utilized, CD1d / alpha GC is loaded into a pore channel of a mesoporous nano-material, and the design can protect protein drugs from being degraded in blood circulation, so that a nano-vaccine capable of effectively mediating iNKT cells and successfully relieving the inability of the iNKT cells is constructed; and the effectiveness of the compound in tumor treatment is verified. The patent is supported by the national natural science fund (82001958).

The invention provides a universal UCMSC and a construction method and application thereof.The construction method includes the steps that a UCMSC specific lipid mixture containing ionizable lipid, auxiliary lipid, a stabilizer and cholesterol is prepared, the UCMSC specific lipid mixture is mixed with a nucleic acid solution containing CRISPRoff mRNA and a targeted B2M gene super enhancer sgRNA, and UCMSC specific LNP is prepared; the optimal universal UCMSC disclosed by the invention is constructed by transfecting P0-generation UCMSC with UCMSC specific LNP and screening a cell subset with low expression of HLA-I, the problems that existing universal cell construction depends on a virus or an electrotransfection system and genome change and immunological rejection exist are solved, and the optimal universal UCMSC has the effects of continuously and stably low immunogenicity, effectively avoiding immunological rejection and being free of permanent genome change. The construction method provided by the invention is safe and reliable, is simple and convenient to operate, improves the clinical accessibility of UCMSC cell therapy, reduces the burden of patients, and has a wide application prospect.

The invention belongs to the field of immunotoxicology, and particularly relates to a method for immunotyping bone marrow cells by flow cytometry. The flow cytometry immune typing method for bone marrow cells comprises the following steps: collecting macaca fascicularis bone marrow fluid, and preparing the macaca fascicularis bone marrow fluid into single-cell suspension; dyeing the obtained cells by using an antibody combination containing a plurality of fluorescent labels; then, a flow cytometer is used for collecting cell fluorescence signals, a standardized gate setting strategy is executed, and based on collected data, the percentage of each cell subset in CD45 + living white blood cells is calculated to complete immune typing. According to the flow cytometry immune typing method for the bone marrow cells, the problems of low efficiency, low repeatability, low sensitivity and poor specificity of related technologies are solved, and more accurate and reliable data support is provided for early discovery, risk assessment and mechanism research of drug immunotoxicity.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

A cancer immunotherapy for treating cancers such as melanoma is presented. A method for treating cancer in a subject via administration of anti-LY6E antibody to the subject. The method can further include administering an IFNAR blockade to inhibit type-1 interferon (IFN) signaling, thereby enhancing the ant-tumoral cytotoxic activity of T cells. The IFNAR can include anti-IFNα. The method can also include administering anti-PD1 antibody prior to, commensurate, or after treatment with anti-LY6E. A composition for treating cancer and modulating immune responses in a subject is also included. The composition can include, among other things, the anti-LY6E antibody, the IFNAR blockade, and anti-PD1. The composition and method also present a mechanism to modulate immune response in a subject by preventing upregulation of a Ly6ahigh T-cell subpopulation in response to a stimulus such as cancer, UVB, or interferons.

The invention discloses a single cell data expression profile reconstruction method based on a cell-gene heterogeneous bipartite graph and related equipment, and belongs to the technical field of bioinformation.The method comprises the steps that the cell-gene heterogeneous bipartite graph is constructed, and embedding of different types of gene nodes and cell nodes is updated through a graph neural network encoder; obtaining an initial cell node representation and an initial gene node representation; constructing global representation of two types of nodes on the whole graph and local representation of nodes on a closed sub-graph based on initial cell node representation and initial gene node representation, inputting the global representation and the local representation into a noise contrast loss function, scoring through a discriminator, obtaining cell node embedding and gene node embedding, and inputting the cell node embedding and the gene node embedding into a matrix decomposition model; and after an objective function is optimized, outputting a reconstructed single cell data expression profile. The method can solve the problem that in the prior art, more original information cannot be reserved when a single cell data expression profile is reconstructed, so that the cell subpopulation cannot be accurately recognized and the cell state cannot be reflected.

The present invention discloses a method for screening tumor prognosis molecular markers specifically expressed by individual sample cell subpopulations. First, the gene expression data is analyzed and decomposed to obtain estimates of population cell subpopulation-specific expression; then, by combining it with clinical information, a prognostic evaluation of population cell subpopulation-specific expression is obtained, and cell subpopulations with significant survival differences are further decomposed to obtain estimates of individual sample cell subpopulation-specific expression; finally, by constructing a co-expression module of cell subpopulations, genes with a high degree of connectivity are obtained as tumor prognosis molecular markers for tumor molecular typing and prognosis evaluation. The invention is applied to breast cancer tumors. The tumor prognosis molecular markers obtained by this method are used to type breast cancer. This is a molecular typing of breast cancer at the level of individual cell subpopulation heterogeneity. This typing method is more capable of explaining the changes and development of the disease in a complex biological environment, laying the foundation for the design of targeted drugs.

The application provides an analysis method, device and equipment based on single-cell transcriptome sequencing data, which comprises the following steps: performing quality control, downstream analysis and visual display on single-cell transcriptome sequencing expression quantitative data, performing cell filtering by using Grubbs test method to obtain effective single-cell transcriptome sequencing quantitative data, performing initialization clustering analysis on the data to obtain single-cell subgroup classification results; performing screening on the single-cell subgroup classification results to obtain target single-cell subgroups, and performing re-clustering analysis to obtain single-cell sub-subgroup classification results; performing significant difference gene screening analysis on the single-cell transcriptome sequencing quantitative data between single-cell subgroups; and performing regression analysis based on characteristic genes of cell cycles to predict cell division periods corresponding to different cell types. The application effectively solves the technical complex problems of existing single-cell transcriptome sequencing quantitative data analysis, makes data analysis more simple and reliable, and reduces the difficulty of data analysis.

The application belongs to the technical field of medical biological detection, and particularly relates to a construction method of a cancer drug efficacy prediction model, a molecular marker for evaluating the prognosis of intrahepatic cholangiocarcinoma obtained by the construction method, and application of the molecular marker in preparation of a reagent or kit for evaluating the prognosis of intrahepatic cholangiocarcinoma. The application provides a construction method of a cancer drug efficacy prediction model, and uses the construction method to evaluate the drug efficacy prediction of intrahepatic cholangiocarcinoma. The method can analyze the cell and transcriptome characteristic differences in the tumor environment of different efficacy patients in a high-throughput and high-resolution manner by capturing and transcriptome sequencing of a large number of cells in the tumor environment of different patients, so as to establish the correlation between the proportion of specific cell subgroups in the tumor before treatment and the efficacy of the patient.

The invention discloses a method for predicting the curative effect of triple negative breast cancer immunotherapy by spatially quantizing CD39 + CD103 + CD8 + T cells, and relates to the technical field of biology.The method comprises the following specific steps that S1, an FFPE tumor tissue sample of a TNBC subject before immunotherapy is obtained, and a continuous section with the thickness of 3-5 microns is prepared and attached to a positive charge glass slide; s2, staining the section by using a combination containing CD8 / CD103 / CD39 / Pan-CK antibodies through a TSA sequential staining method, and then re-staining cell nucleuses by using DAPI; according to the method, spatial quantitative analysis is performed on a specific CD39 + CD103 + CD8 + T cell subset, a percentage index of target cells in CD8 + T cells and an average distance index of the target cells and nearest Pan-CK positive cells in a cancer nest region are set, and the target cells are determined according to comparison between the two indexes and a preset threshold value. According to the method, whether a subject is a potential benefit crowd treated by an anti-PD-1 / PD-L1 immune checkpoint inhibitor or not is accurately judged, a standardized technical means is provided for clinically screening the potential benefit crowd for immunotherapy, the accuracy and effectiveness of triple-negative breast cancer immunotherapy are effectively improved, and invalid treatment is reduced.

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.